-
Prevalence of Pediatric Inflammatory Bowel Disease in the United States: Pooled Estimates from Three Administrative Claims Data Sources Gastroenterology (IF 25.7) Pub Date : 2024-11-20 Michael D. Kappelman, Colleen Brensinger, Lauren E. Parlett, Andres Hurtado-Lorenzo, James D. Lewis
No Abstract
-
Reply to Liang et al Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Alice Boilève, Michel Ducreux, Fanny Jaulin
No Abstract
-
PDO-Based Drug Screening in Advanced Pancreatic Cancer: Addressing Predictive Value and Broader Clinical Implications Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Chaojie Liang, Dan Shan, Zhigang Wei
No Abstract
-
Faecal phageome transplantation alleviates intermittent intestinal inflammation in IBD and the timing of transplantation matters: a preclinical proof-of-concept study in mice Gut (IF 23.0) Pub Date : 2024-11-19 Nengneng Li, Yue Li, Ziyu Huang, Zhirui Cao, Cha Cao, Xiang Gao, Tao Zuo
We read with interest the Rome Consensus paper on faecal microbiota transplantation (FMT) in IBD (a refractory disease with intermittent flare-ups and remissions of intestinal inflammation) by Lopetuso et al .1 It highlights modest efficacies of FMT in treating IBD and adverse event risks caused by bacteria transplantation, according to data from clinical trials.1 Hence, further refinement of FMT is
-
Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome Gut (IF 23.0) Pub Date : 2024-11-19 Laura J Schwarzmueller, Ronja S Adam, Leandro F Moreno, Lisanne E Nijman, Adrian Logiantara, Steven Eleonora, Oscar Bril, Sophie Vromans, Nina E de Groot, Francesca Paola Giugliano, Ekaterina Stepanova, Vanesa Muncan, Clara C Elbers, Kristiaan J Lenos, Danny A Zwijnenburg, Monique A J van Eijndhoven, Dirk Michiel Pegtel, Sanne M van Neerven, Fabricio Loayza-Puch, Tulin Dadali, Wendy J Broom, Martin
Background Aberrant Wnt pathway activation is a key driver of colorectal cancer (CRC) and is essential to sustain tumour growth and progression. Although the downstream protein-coding target genes of the Wnt cascade are well known, the long non-coding transcriptome has not yet been fully resolved. Objective In this study, we aim to comprehensively reveal the Wnt-regulated long non-coding transcriptome
-
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study Gut (IF 23.0) Pub Date : 2024-11-19 Jinsei Miyoshi, Alessandro Mannucci, Marco Scarpa, Feng Gao, Shusuke Toden, Timothy Whitsett, Landon J Inge, Ross M Bremner, Tetsuji Takayama, Yulan Cheng, Teodoro Bottiglieri, Iris D Nagetaal, Martha J Shrubsole, Ali H Zaidi, Xin Wang, Helen G Coleman, Lesley A Anderson, Stephen J Meltzer, Ajay Goel
Background There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s oesophagus (BE). Objective To develop and test a blood-based assay for EAC and BE. Design Oesophageal MicroRNAs of BaRRett, Adenocarcinoma and Dysplasia ( EMERALD ) was a large, international, multicentre biomarker cohort study involving 792 patient
-
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-11-18 Geert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, Pilar Nos, Silvio Danese, Alessandro Armuzzi, Xavier Roblin, Laurent Peyrin-Biroulet, Rachel West, Wout G N Mares, Marjolijn Duijvestein, Krisztina B Gecse, Brian G Feagan, Guangyong Zou, Melanie S Hulshoff, Aart Mookhoek, Lotte Oldenburg, Esmé Clasquin, Yoram Bouhnik, David Laharie
BackgroundApproximately half of patients with Crohn's disease require ileocolonic resection. Of these, 50% will subsequently have endoscopic disease recurrence within 1 year. We aimed to evaluate the efficacy and safety of vedolizumab to prevent postoperative recurrence of Crohn's disease. MethodsREPREVIO was a double-blind, randomised, placebo-controlled trial conducted at 13 academic or teaching
-
Vedolizumab prophylaxis against postoperative Crohn's disease recurrence Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-11-18 Robert J Mulligan, Christopher A Lamb
No Abstract
-
Hypoxic and acidic tumor microenvironment-driven AVL9 promotes chemoresistance of pancreatic ductal adenocarcinoma via the AVL9-IκBα-SKP1 complex Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Jinsheng Ding, Yongjie Xie, Ziyun Liu, Zhaoyu Zhang, Bo Ni, Jingrui Yan, Tianxing Zhou, Jihui Hao
Background & AimsGemcitabine combined with albumin-paclitaxel (AG) is a crucial therapeutic option for pancreatic ductal adenocarcinoma (PDAC). However, the response to chemotherapy is relatively poor, with rapid development of resistance. The aim of this study was to explore the mechanism of resistance to AG and to develop strategies that can sensitize the AG regimen. MethodsWe utilized organoid models
-
-
-
-
Elsewhere in The AGA Journals (Preview Section) Gastroenterology (IF 25.7) Pub Date : 2024-11-19
No Abstract
-
Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Federica Di Vincenzo, Maria A. Quintero, Payton Mendygral, Maria T. Abreu
No Abstract
-
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, John P. Haydek, Manasi Agrawal, Frank I. Scott, Ashwin N. Ananthakrishnan
Background & AimsThis American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC). MethodsA multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical
-
Spotlight: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Gastroenterology (IF 25.7) Pub Date : 2024-11-19 Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, John P. Haydek, Manasi Agrawal, Frank I. Scott, Ashwin N. Ananthakrishnan
No Abstract
-
CME Exam 1: An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk Gastroenterology (IF 25.7) Pub Date : 2024-11-19
Section snippets CME/MOC CreditsThe AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The AGA Institute designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
-
Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-19 Simon Woelfel, Stephan Brand
We thank Drs. Alexander and Caldera for their stimulating and compelling editorial that excellently contextualised our study evaluating the immunogenicity of original and variant-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease (IBD) and healthy controls [1, 2]. To date, the STAR SIGN study has evaluated immunity against wild-type SARS-CoV-2 and the omicron BA.1, BA5, BQ.1
-
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-19 Konstantinos Papamichael, Adam S. Cheifetz
Numerous exposure–outcome relationship studies demonstrate a positive correlation between therapeutic biologic drug concentrations and favourable outcomes in immune-medicated inflammatory disorders including inflammatory bowel disease (IBD) [1, 2]. In the same vein, low drug concentrations are associated with loss of response and immunogenicity [1, 3]. Furthermore, post hoc analyses of randomised controlled
-
High-density lipoprotein lipidome: a neglected source of hepatic lipids Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Gabriele Mocciaro
To define the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and identify therapeutic options, it is crucial to understand the sources of hepatic fat accumulation. In patients with MASLD, it is estimated that hepatic triglycerides are primarily derived from adipose tissue as free fatty acids (~59%), followed by de novo lipogenesis (~26%) and diet (~15%). However
-
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Valeria Fumagalli, Matteo Iannacone
-
Transforming the landscape of liver cancer detection and care Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Terry Cheuk-Fung Yip, Grace Lai-Hung Wong
-
Microbiota-derived small molecule genotoxins: host interactions and ecological impact in the gut ecosystem. Gut Microbes (IF 12.2) Pub Date : 2024-11-18 Ellen L Zechner,Sabine Kienesberger
The human intestinal tract is densely colonized by a microbial community that is subject to intense competition. Bacteria in this complex habitat seek to outcompete their neighbors for nutrients and eliminate competitors with antibacterial toxins. Antagonism can be mediated by diverse effectors including toxic proteins and small molecule inhibitors that are released extracellularly or delivered by
-
Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-18 Sung Noh Hong, Joo Hye Song, Sung Jin Kim, Yoon Ha Park, Chang Wan Choi, Ji Eun Kim, Eun Ran Kim, Dong Kyung Chang, Young‐Ho Kim
-
Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-18 Giovanni Cammarota, Lucrezia Laterza, Stefano Bibbò, William Fusco, Tommaso Rozera, Eugenio Di Brino, Serena Porcari, Franco Scaldaferri, Gianluca Ianiro, Antonio Gasbarrini, Alessandro Armuzzi
-
Effects of gastric bypass bariatric surgery on gut microbiota in patients with morbid obesity. Gut Microbes (IF 12.2) Pub Date : 2024-11-17 Urja Amin,Dora Huang,Arun Dhir,Anya E Shindler,Ashley E Franks,Colleen J Thomas
The Western diet is associated with gastrointestinal dysbiosis, an active contributor to the pathophysiology of obesity and its comorbidities. Gastrointestinal dysbiosis is strongly linked to increased adiposity, low-grade inflammation, dyslipidaemia, and insulin resistance in individuals with morbid obesity. Bariatric bypass surgery remains the most effective treatment for achieving significant weight
-
Dysrupted microbial tryptophan metabolism associates with SARS-CoV-2 acute inflammatory responses and long COVID. Gut Microbes (IF 12.2) Pub Date : 2024-11-17 Lu Yao,Hannah Devotta,Junhui Li,Nonhlanhla Lunjani,Corinna Sadlier,Aonghus Lavelle,Werner C Albrich,Jens Walter,Paul W O'Toole,Liam O'Mahony
Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and risk of long COVID has been associated with the depletion or over-abundance of specific taxa within the gut microbiome. However, the microbial mechanisms mediating these effects are not yet known. We hypothesized that altered microbial production of tryptophan and its downstream derivatives might contribute
-
AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review Gastroenterology (IF 25.7) Pub Date : 2024-11-16 Michael J. Bourke, Simon K. Lo, Ross C.D. Buerlein, Koushik K. Das
DescriptionNonampullary duodenal polyps are found in up to 5% of all upper endoscopies; the vast majority are identified incidentally in asymptomatic patients. Although most are benign, adenomas are estimated to account for 10%–20% of these lesions. Most international guidelines recommend that all duodenal adenomas should be considered for endoscopic resection; this may be associated with a near 15%
-
Expanding the Differential Diagnosis: Severe, Swollen Hepatocytes in a Patient with an ALT above 1000 U/L Gastroenterology (IF 25.7) Pub Date : 2024-11-16 Michael Eller, Lindsey Westbrook, Avash Kalra
No Abstract
-
Devices substitution can reduce environmental burden: what about strategies substitution? Gut (IF 23.0) Pub Date : 2024-11-15 Raphaëlle Grau, Jérémie Jacques, Jérôme Rivory, Mathieu Pioche
We read with great interest the article by Henniger et al 1 about reducing scope 3 carbon emissions in endoscopy and would like to discuss several points. First, we commend the study’s transparency, as manufacturers provided detailed information about their fabrication and delivery processes. This collaboration exemplifies our shared goal of environmental protection. Furthermore, this is the first
-
Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-16 Andrew T. Roberts, Joseph Makar, Jonathan Abdelmalak, Marie Sinclair, Adam Testro, Avik Majumdar
-
Prebiotics in food and dietary supplements: a roadmap to EU health claims. Gut Microbes (IF 12.2) Pub Date : 2024-11-15 Kieran Tuohy,Elaine E Vaughan,Lucien F Harthoorn,Ellen E Blaak,Philip W J Burnet,Alessandro Busetti,Anirikh Chakrabarti,Nathalie Delzenne,Paul de Vos,Louise Dye,Damien Guillemet,Lesley A Houghton,Alwine F M Kardinaal,Cath Mersh,Kathy Musa-Veloso,Annegret Nielsen,Justyna Palasinska,Seppo Salminen,Gemma Walton,Naomi Venlet,Charlotte Hubermont,Philip C Calder
Numerous studies have established that prebiotic ingredients in foods and dietary supplements may play a role in supporting human health. Over the three decades that have passed since prebiotics were first defined as a concept, research has revealed a complex universe of prebiotic-induced changes to the human microbiota. There are strong indications of a direct link between these prebiotic-induced
-
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-15 Mohsin F. Butt, Maura Corsetti
The Rome criteria, first published in 1994 and currently in their fourth iteration, are widely considered to be the gold standard symptom-based criteria to diagnose disorders of gut-brain interaction (DGBI), formerly known as functional gastrointestinal diseases [1]. To inform the upcoming Rome V criteria, due for publication in 2026, the Rome Foundation analysed the effects of modifying symptoms (e
-
Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-15 Angelica Rivas, Newaz Shubidito Ahmed, Yuhong Yuan, Anila Qasim, David B. O'Gorman, Brian G. Feagan, Vipul Jairath, Albert J. Bredenoord, Evan S. Dellon, Christopher Ma
-
High serum pesticide levels are associated with increased odds of inflammatory bowel disease in a nested case-control study Gastroenterology (IF 25.7) Pub Date : 2024-11-14 Manasi Agrawal, Ryan C. Ungaro, Palak Rajauria, Jared Magee, Lauren Petrick, Vishal Midya
No Abstract
-
AGA Clinical Practice Update on Endoscopic Enteral Access: Commentary Gastroenterology (IF 25.7) Pub Date : 2024-11-14 Dejan Micic, John A. Martin, John Fang
DescriptionThe purpose of this American Gastroenterological Association (AGA) Clinical Practice Update is to facilitate understanding and improve the clinical practice of endoscopic enteral access. MethodsThis expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance
-
Induction of intercrypt goblet cells upon bacterial infection: a promising therapeutic target to restore the mucosal barrier. Gut Microbes (IF 12.2) Pub Date : 2024-11-14 Renaud Léonard,Ewa Pasquereau-Kotula,Edwige Madec,Benjamin Marsac,Adriana Mihalache,Laurence du Merle,Jordan Denis,Corentin Spriet,Philippe Sansonetti,Shaynoor Dramsi,Catherine Robbe Masselot
Intestinal mucins play a crucial role in the mucosal barrier, serving as the body's initial defense against microorganisms. However, how the host regulates the secretion and glycosylation of these mucins in response to bacterial invasion remains unclear. Our study demonstrates that when exposed to Streptococcus gallolyticus (SGG), a gut pathobiont, the host mucosa promptly adjusts the behavior of specialized
-
Mechanisms of gut bacterial metabolism of dietary polyphenols into bioactive compounds. Gut Microbes (IF 12.2) Pub Date : 2024-11-14 Sara Alqudah,Jan Claesen
The fruits and vegetables we consume as part of our diet are rich in bioactive metabolites that can prevent and ameliorate cardiometabolic diseases, cancers, and neurological conditions. Polyphenols are a major metabolite family that has been intensively investigated in this context. However, for these compounds to exert their optimal bioactivity, they rely on the enzymatic capacity of an individual's
-
TEMPORARY REMOVAL: QUALITY INDICATORS FOR UPPER GI ENDOSCOPY Gastrointest. Endosc. (IF 6.7) Pub Date : 2024-11-14 Rena Yadlapati MD MS, Dayna Early MD, Prasad G. Iyer MD MS, Douglas R. Morgan MD MPH, Neil Sengupta MD, Prateek Sharma MD, Nicholas J. Shaheen MD MPH
The publisher regrets that this article has been posted prematurely. The article has been temporarily removed and will be reinstated as soon as possible.
-
Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Francesco Paolo Russo, Alberto Ferrarese
Acute-on-chronic liver failure (ACLF) is a severe condition characterised by high short-term mortality, requiring rapid diagnosis, prompt treatment of trigger factors and appropriate prognostic evaluation to guide patients towards the best therapeutic options. Although several scores, such as the model for end-stage liver disease (MELD) and the CLIF-C ACLF score, have been proposed over time to assess
-
Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Jiong Yu, Xinyi Chen, Guoqiang Cao, Qiaoling Pan, Chenjie Huang, Rui Luo, Xiaoqing Lu, Xiaoxiao Chen, Tan Li, Haijun Huang, Jian Wu, Lanjuan Li, Hongcui Cao
We extend our sincere gratitude to Dr. Francesco Paolo Russo and Alberto Ferrarese for their thorough evaluation and professional insights on our study [1]. We are gratified by their recognition of the potential of the age-adjusted Charlson Comorbidity Index for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure (aCCI-HBV-ACLF) score in enhancing the accuracy of short-term and medium-term prognostic
-
Letter: Insulin‐Like Growth Factor‐1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver‐Related Mortality Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Okasha Tahir, Muhammad Muzamil Rafique, Abdul Ghani Khan, Asia Rajab, Umama Alam, Muhammad Umar, Laiba Shamim, Ayesha Hidayat
We read the article published in your esteemed journal titled, “Insulin-like growth factor-1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver-related mortality” by Hartl et al. with great interest. We appreciate the authors for investigating the prognostic role of insulin-like growth factor-1 (IGF-1) in advanced chronic liver disease (ACLD) patients [1]. While the study
-
It is time for World Hepatitis Testing Week Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-11-12 Rachel Halford, Jessica Hicks, Reazul Islam, Cary James, Luís Mendão, Gamal Shiha, Alexandra Smith, Patricia Vélez-Möller
No Abstract
-
Sucrase isomaltase dysfunction reduces sucrose intake in mice and humans Gastroenterology (IF 25.7) Pub Date : 2024-11-13 Peter Aldiss, Leire Torices, Stina Ramne, Marit Eika Jørgensen, Mauro D’Amato, Mette K. Andersen
No Abstract
-
Exploring the Potential of Real-Time Audio-Visual Interactions of ChatGPT-4o in Endoscopy Training and Practice Gastroenterology (IF 25.7) Pub Date : 2024-11-13 Qiqi Wu
No Abstract
-
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases Gut (IF 23.0) Pub Date : 2024-11-12 Yuanfang Li, Yongqiang Zheng, Jiaqian Huang, Run-Cong Nie, Qi-Nian Wu, Zhijun Zuo, Shuqiang Yuan, Kai Yu, Cheng-Cai Liang, Yi-Qian Pan, Bai-Wei Zhao, Yuhong Xu, Qihua Zhang, Yashang Zheng, Junquan Chen, Zhao-Lei Zeng, Wei Wei, Ze-Xian Liu, Rui-Hua Xu, Hui-Yan Luo
Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer peritoneal metastasis (GCPM) have a poor prognosis and respond poorly to conventional treatments. Recently, immune checkpoint blockade (ICB) has demonstrated favourable efficacy in the treatment of GCPM. Stratification of best responders and elucidation of resistance mechanisms of
-
Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD Gut (IF 23.0) Pub Date : 2024-11-12 Judith Wellens, João Sabino, Tim Vanuytsel, Jan Tack, Séverine Vermeire
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a diagnosis of IBS cannot be made, the prevalence of ‘IBS in IBD’ surpasses the rate of IBS in the global population by fivefold. Because IBS-like symptoms are associated with a decreased quality of life and increased healthcare utilisation in IBD, diagnosis and treatment are necessary
-
Large proximal gastric GIST tumours: downsizing by imatinib and subsequent endoresection Gut (IF 23.0) Pub Date : 2024-11-12 Ayimukedisi Yalikong, Baohui Song, Dongli He, Enpan Xu, Zhipeng Qi, Yunshi Zhong
Surgical removal is recommended for gastrointestinal stromal tumours (GISTs) larger than 3 cm due to their potential for malignancy but limited wedge resection is not possible in the proximal stomach. Endoscopic removal of larger lesions has been technically limited in complex anatomical regions such as cardia. We report two cases of large proximal (cardia/fundus) GIST tumours (51 and 60 mm) which
-
Lactic acid bacteria derived extracellular vesicles: emerging bioactive nanoparticles in modulating host health. Gut Microbes (IF 12.2) Pub Date : 2024-11-13 Mohan Li,Bingyong Mao,Xin Tang,Qiuxiang Zhang,Jianxin Zhao,Wei Chen,Shumao Cui
Lactic acid bacteria derived extracellular vesicles (LAB-EVs) are nano-sized and carry a variety of biological cargoes. LAB-EVs have proven to be potential mediators of intercellular communication, serving not only the parental bacteria but also the host cell in both physiology and pathology. LAB-EVs are therapeutically beneficial in various diseases through a cell-free strategy. Particularly, EVs
-
Differential contributions of the gut microbiota and metabolome to pathomechanisms in ulcerative colitis: an in vitro analysis. Gut Microbes (IF 12.2) Pub Date : 2024-11-13 Jonas Poppe,Leen Boesmans,Sara Vieira-Silva,Lise Deroover,Raul Tito,Doris Vandeputte,Greet Vandermeulen,Vicky De Preter,Jeroen Raes,Severine Vermeire,Gwen Falony,Kristin Verbeke
The gut microbiota has been implicated in onset and progression of ulcerative colitis (UC). Here, we assess potential causal involvement of the microbiota and -associated fecal water (FW) metabolome in altering key functional parameters of the colonic epithelium. Fecal samples were collected from N = 51 healthy controls (HC), N = 36 patients with active UC (UC-A), and N = 41 subjects in remission N = 41
-
Gut microbial metabolism of bile acids modifies the effect of Mediterranean diet interventions on cardiometabolic risk in a randomized controlled trial. Gut Microbes (IF 12.2) Pub Date : 2024-11-13 Peipei Gao,Ehud Rinott,Danyue Dong,Zhendong Mei,Fenglei Wang,Yuxi Liu,Omer Kamer,Anat Yaskolka Meir,Kieran M Tuohy,Matthias Blüher,Michael Stumvoll,Meir J Stampfer,Iris Shai,Dong D Wang
Bile acids (BAs) undergo extensive microbial metabolism in the gut and exert hormone-like functions on physiological processes underlying metabolic risk. However, the extent to which gut BA profiles predict cardiometabolic risk and explain individual responses to dietary interventions in humans is still unclear. In the DIRECT-PLUS Trial, we conducted a multi-omics analysis of 284 participants randomized
-
Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-13 Virginia Solitano, Guangyong Zou, Vipul Jairath
We thank Dr. Schildkraut et al. for their thoughtful commentary and the acknowledgment of the importance of our study in demonstrating that existing bowel preparation quality assessment instruments, typically used in the general population, are also reliable and valid for patients with Crohn's disease (CD) [1]. The implications of these findings are that instrument selection for use in clinical practice
-
Letter: Bowel Preparation Quality in Patients With Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-13 Tamar Schildkraut, Nik (John) S. Ding, John David Chetwood
Adequate bowel preparation is crucial for optimal visualisation and lesion detection and remains a key determinant of colonoscopy quality [1, 2]. Up to one-quarter of colonoscopies are conducted with inadequate bowel preparation, leading to reduced diagnostic yield and detection of nonpolypoid flat lesions, prolonged procedure time and an increased burden of repeat colonoscopies [2, 3]. Several validated
-
Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-10 Mitchell Shiffman, K. Rajender Reddy, Michael D. Leise, Kamran Qureshi, Alastair D. Smith, Steve Helmke, John Kittelson, Michael P. McRae, Joanne C. Imperial, Gregory T. Everson
-
A new treatment and updated clinical practice guidelines for MASLD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-11 Elizabeth E. Powell
-
Metabolic health across the ages: how microbiota members support our well-being Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-11 Carolina Tropini
-
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg) Gut (IF 23.0) Pub Date : 2024-11-11 Llum Olmedo, Xavier Calvet, Emili Gené, Dmitry S Bordin, Irina Voynovan, M Castro-Fernandez, Manuel Pabón-Carrasco, Alma Keco-Huerga, Ángeles Perez-Aisa, Alfredo J Lucendo, Luís Rodrigo, Aiman S Sarsenbaeva, Igor B Khlinov, Galyna Fadieienko, Oleg Zaytsev, Ángel Lanas, Samuel J Martínez-Domínguez, Enrique Alfaro, Laimas Jonaitis, Óscar Núñez, Rinaldo Pellicano, Luis Hernández, Oleksiy Gridnyev, Juozas
Background Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Objective To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management
-
Stability in fecal metabolites amid a diverse gut microbiome composition: a one-month longitudinal study of variability in healthy individuals. Gut Microbes (IF 12.2) Pub Date : 2024-11-12 Matteo Sangermani,Indri Desiati,Solveig M Jørgensen,Jia V Li,Trygve Andreassen,Tone F Bathen,Guro F Giskeødegård
An extensive network of microbial-host interactions exists in the gut, making the gut microbiome a complex ecosystem to untangle. The microbial composition and the fecal metabolites are important readouts to investigate intricate microbiota-diet-host interplay. However, this ecosystem is dynamic, and it is of interest to understand the degree and timescale of changes occurring in the gut microbiota
-
Preliminary results from a multicenter, randomized trial using fecal microbial transplantation to induce remission in patients with mild to moderate Crohn's disease. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2024-11-12 Dina Kao,Karen Wong,Humberto Jijon,Paul Moayyedi,Rose Franz,Chelsea McDougall,Naomi Hotte,Remo Panaccione,Eric Semlacher,Karen I Kroeker,Farhad Peerani,Karen V MacDonald,Huiping Xu,Neeraj Narula,Christian Turbide,Deborah A Marshall,Karen L Madsen
INTRODUCTION Fecal microbial transplantation (FMT) has shown promise at inducing remission in ulcerative colitis. This study is the first of its kind to evaluate the efficacy and safety of FMT at inducing remission in Crohn's disease (CD). METHODS This double-blind, placebo-controlled trial was conducted in three Canadian academic centers; randomized patients with mild to moderate CD received FMT or
-
Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities and Outcomes. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2024-11-12 Marina Serper,Marya E Pulaski,Siqi Zhang,Tamar H Taddei,David E Kaplan,Nadim Mahmud
BACKGROUND Intravenous albumin reduces mortality in SBP. We sought to characterize albumin use for SBP over time and investigate patient and hospital-level factors associated with use. METHODS A retrospective cohort study in the Veterans Health Administration between 2008 and 2021 evaluated trends and patient, practice-, and facility-level factors associated with use among patients with cirrhosis hospitalized